<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03553537</url>
  </required_header>
  <id_info>
    <org_study_id>D-CHOP study</org_study_id>
    <nct_id>NCT03553537</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma</brief_title>
  <official_title>Multi-center Randomized Study to Compare Efficacy and Safety of Decitabine Plus CHOP (D-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southwest Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective of the study is to compare the efficacy and safety of decitabine plus CHOP
      (D-CHOP) versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma
      (PTCL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, multi-center, open-label study to compare efficacy and safety of D-CHOP
      with standard CHOP regimen in patients with previously untreated PTCL. Study subjects are
      patients with histologically proven PTCL. Patients are randomized 1:1 to receive either
      cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week
      cycles for 6 cycles or decitabine plus CHOP (D-CHOP) administered in 4 week cycles for 6
      cycles. In the D-CHOP arm, decitabine will be administered at a dose of 10 mg/m² IV on day
      1-5 every 3 weeks. This study is divided into three phases: screening phase, treatment phase
      and follow-up phase. Patients will receive study drug(s) for up to 6 cycles, or until
      unacceptable toxicity will develop or progression or voluntary withdrawal.Adverse event of
      every treatment cycle will be recorded.Therapy efficacy will be evaluated after finishing 3
      cycles and finishing 6 cycles therapy. Patients will be followed until disease progression,
      died or 2 years from the last patient randomized.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>3 years</time_frame>
    <description>from date of inclusion to date of progression, relapse, or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
    <description>from the date of inclusion to date of death, irrespective of cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>3 years</time_frame>
    <description>complete response (CR) and partial response (PR) rates, using the standard response criteria (Cheson and al.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>3 years</time_frame>
    <description>any unfavorable and unintended sign , symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Peripheral T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Decitabine + CHOP regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>decitabine plus CHOP (D-CHOP) administered in 4 week cycles for 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHOP regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>10mg/m² iv on day 1-5</description>
    <arm_group_label>Decitabine + CHOP regimen</arm_group_label>
    <other_name>5-aza-2'-deoxycytidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>750mg/m² iv on day 6</description>
    <arm_group_label>CHOP regimen</arm_group_label>
    <arm_group_label>Decitabine + CHOP regimen</arm_group_label>
    <other_name>CTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>DOX</description>
    <arm_group_label>CHOP regimen</arm_group_label>
    <arm_group_label>Decitabine + CHOP regimen</arm_group_label>
    <other_name>50mg/m² iv on day 6</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>1.4mg/m² iv on day 6</description>
    <arm_group_label>CHOP regimen</arm_group_label>
    <arm_group_label>Decitabine + CHOP regimen</arm_group_label>
    <other_name>VCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>100mg/m² po on day6-10</description>
    <arm_group_label>CHOP regimen</arm_group_label>
    <arm_group_label>Decitabine + CHOP regimen</arm_group_label>
    <other_name>PED</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically proven untreated peripheral T-cell lymphoma (include PTCL
             not otherwise specified, angioimmunoblastic T cell lymphoma, anapestic large cell
             lymphoma, enteropathy-associated T cell lymphoma, Monomorphic epitheliotropic
             intestinal T-cell lymphoma, Nodal peripheral T-cell lymphoma with TFH phenotype and
             Follicular T-cell lymphoma).

          2. Males and females of 18 years of age to 80 years of age.

          3. Patients have not received anti-tumor therapy.

          4. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.

          5. Fit chemotherapy indications and basic requirements, including no obvious abnormal
             function of heart, liver, lung and kidney: creatine ≤2.0×ULN, total bilirubin
             ≤2.0mg/dl, transaminases≤3×ULN.

          6. Normal peripheral hemogram: ANC≥1.5×10^9/L, Hb≥90g/L, PLT≥100×10^12/L.

          7. None of other serious disease conflict with the therapeutic regimen.

          8. None of other malignant tumor.

          9. Pregnancy test of women at reproductive age must be negative.

         10. Estimated survival time ≥ 3 months with good compliance.

         11. Voluntary participation, cooperate with the experimental observation, and sign a
             written informed consent.

        Exclusion Criteria:

          1. Patients with the following PTCL subtypes are excluded; extranodal NNK/T-cell
             lymphoma, T-prolymphocytic leukemia, T large granular lymphocytic leukemia, chronic
             lymphoproliferative disorder of NK cells, aggressive natural killer-cell leukemia,
             adult T-cell leukemia/ lymphoma, hepatosplenic T-cell lymphoma, subcutaneous
             panniculitis-like T-cell lymphoma, cutaneous T cell lymphoma, breast
             implant-associated anaplastic large-cell lymphoma.

          2. Transformed lymphoma.

          3. Patients with other malignancies in the past or now; or secondary lymphoma triggered
             by chemotherapy or radiotherapy of other malignancies.

          4. Already initiated lymphoma therapy (exept for the prephase treatment specified for
             this study).

          5. Patients with primary central nervous system lymphoma or lymphoma involving central
             nervous system.

          6. Patients who have central nervous system or meninges involvements.

          7. Candidate for hematopoietic stem cell transplantation.

          8. Known hypersensitivity to medications to be used.

          9. Hemogram abnormality: ANC&lt;1.5×10^9/L; or HGB&lt;90 g/L; or PLT&lt;100×10^9/L.

         10. Known hepatic and renal insufficiency (creatine&gt;2.0×ULN, total bilirubin&gt;2.0
             mg/dl，transaminases&gt;3.0×ULN).

         11. Patients with decompensated heart failure; or with dilated cardiomyopathy; or with
             coronary heart disease of non-corresponding ST-segment in ECG diagnosis; or with
             myocardial infarction within 6 months.

         12. Patients with serious uncontroled acute infection need to be treated with antibody
             therapies, or antiviral therapies; or serious accompanying disorder or impaired organ
             function.

         13. Know HIV-positivity; or HbsAg positivity; or HCV-Ab positivity.

         14. Pregnancy or lactation period.

         15. Patients who participated in other clinical trials within 3 months.

         16. The researchers considered that patients should not be in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jieping Chen, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Hospital, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xi Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Hospital, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jieping Chen, MD</last_name>
    <phone>+86 13983766908</phone>
    <email>chenjpxn@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xi Li, MD</last_name>
    <phone>+86 15223038417</phone>
    <email>lixi1988xn@163.com</email>
  </overall_contact_backup>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 30, 2018</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2018</study_first_posted>
  <last_update_submitted>May 30, 2018</last_update_submitted>
  <last_update_submitted_qc>May 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southwest Hospital, China</investigator_affiliation>
    <investigator_full_name>Jieping Chen</investigator_full_name>
    <investigator_title>Head of Hematology Department</investigator_title>
  </responsible_party>
  <keyword>Peripheral T-cell Lymphoma, decitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

